Previous close | 10.82 |
Open | 10.84 |
Bid | 10.82 x 1800 |
Ask | 10.85 x 900 |
Day's range | 10.83 - 10.84 |
52-week range | 10.05 - 11.68 |
Volume | |
Avg. volume | 38,087 |
Market cap | 209.942M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 51.62 |
EPS (TTM) | 0.21 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 20.00 |
The Avertix Guardian™ System, the first and only FDA approved implantable heart attack warning system, now available at the Heart & Rhythm Institute of Trinity, extending their commitment to redefining cardiac care in the Tampa, FL area Dr. Luis R. Annoni-Suau, MD, FACC and Dr. Carlos J. Bayron successfully performed the first two Guardian implants at the Heart and Rhythm Institute of Trinity EATONTOWN, N.J. and TRINITY, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or
Recently served as Boston Scientific Executive Vice President and Global Chief Medical Officer Professor Meredith brings to Avertix over 35 years of cardiology experience and commitment to advancing cardiac care EATONTOWN, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), formerly known as Angel Medical Systems, Inc., a healthcare technology company commercializing the first and only FDA-approved heart attack warning system to improve long-term managemen
AdventHealth Orlando performs their first implant of Guardian™ System, revolutionizing cardiac care in Central FloridaEATONTOWN, N.J. and ORLANDO, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and AdventHealth Orlando, a nationally-ranked hospital system